Feed / INBX

Inhibrx Biosciences, Inc.

INBX

Healthcare · 101.77 +10.1% today

Participation confirmed · construction unavailableMarket checked 19 Aug, 15:55 GMT-4

Jodie situation report

Inhibrx Biosciences, Inc.'s move is being confirmed by its market group.

No new filing conclusion is available. 28 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.

Company+10.1% todayVolume comparison unavailable
Market group28 of 31 activeBiotechnology Therapeutics · active
Disclosed network0 of 3 confirmingNo filing-linked name is confirming now
What would change this read
  • At least 21 of 31 members remain active in the next snapshot.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as NRIX begins moving with the group.

Invalidation: The live read weakens if participation falls to 10 of 31 members or fewer.

Watch this read

Who this business touches

The relationships behind INBX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

REGNRegeneron Pharmaceuticals, Inc.partnerNov 14, 2025

Regeneron In June 2020, the Company entered into an Option and License Agreement with bluebird bio, Inc., or bluebird, pursuant to which the Company granted to bluebird exclusive worldwide rights to develop binders and cell therapy products containing single…

SNYSanofiinvesteeNov 14, 2025

On May 30, 2024, the Former Parent completed the Merger, pursuant to which (i) all assets and liabilities primarily related to INBRX-101, or the 101 Business, were transferred to the Acquirer, a wholly-owned subsidiary of Sanofi; and (ii) by way of a series o…

Depended on by

BCAXBicara Therapeutics Inc.competitorMar 30, 2026

In addition, there are numerous companies that are developing new treatments for HNSCC, including but not limited to Akeso, Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., BioAtla Inc., BioNTech SE, Corbus Pharmaceuticals Holdings Inc., GSK plc, InhibRx Bi…

Filing peers

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

INBX is currently a Leader in the organic co-movement group Biotechnology Therapeutics. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.